Lorenza Rimassa

La scandalosa nomina dei due medici idoli dei no-vax nel comitato per le politiche vaccinali - Valigia Blu Il governo italiano ha nominato nel comitato tecnico consultivo per le politiche vaccinali due figure controverse: Paolo Bellavite ed Eugenio Serravalle, noti per le loro posizioni critiche sull’obbli...

💈 La scandalosa nomina dei due medici idoli dei no-vax nel comitato per le politiche vaccinali
www.valigiablu.it/schillaci-no...

3 Out of 5 Liver Cancer Cases Are Preventable, Study Finds

Proud and honored to be part of @thelancet.com Commission on #livercancer #HCC.
3 Out of 5 Liver Cancer Cases Are Preventable, Study Finds www.nytimes.com/2025/07/28/w...

The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment Liver cancer is the sixth most common cancer and the third leading cause of cancer-related mortality globally. The number of new liver cancers will nearly double, from 0·87 million in 2022 to 1·52 mil...

The global burden of #livercancer is increasing. 📈
#HCC accounts for approx. 80% of cases globally.
💡 Proud and honored to be part of the new Commission which outlines evidence-based recommendations for action to reduce the global HCC burden: www.thelancet.com/journals/lan...
@thelancet.com

Dr. Dario Trapani - Global Oncology: Yvonne Awards 2025 Dr. Dario Trapani is an Italian-born medical oncologist, global cancer policy expert, and academic. He currently serves as Assistant Professor

Dr. Dario Trapani – Global Oncology: Yvonne Awards 2025

oncodaily.com/insight/dr-d...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Promotional card for The Lancet Commission on hepatocellular carcinoma. Background image depicts a computer-generated illustration of a human torso with an inflamed liver.

The global burden of liver cancer is increasing. 📈

Hepatocellular carcinoma (HCC) accounts for approximately 80% of cases globally.

💡 A new Commission outlines evidence-based recommendations for action to reduce the global HCC burden: tinyurl.com/yzxvktkw

Incredibly proud to be part of @thelancet.com Commission on #HCC

How we treat patients with advanced #BTC #CCA from #ESMOGI25. Expert centers, MDTs, molecular profiling, chemo-immunotherapy, and targeted agents @vjoncology.bsky.social

Expert-led Post-#ASCO2025 & #ESMOGI2025 Highlights webinars 💻📍

The #GICancer session will be chaired by
@lorenzarimassa.bsky.social & moderated by Richard Kim, Filippo Pietrantonio & Efrat Dotan

AGENDA 👉 buff.ly/NtN20KG

REGISTER 👉 buff.ly/4Z7VyTB

Glad to chair the @vjoncology.bsky.social webinar on #GI cancer and discuss the most important data presented at #ASCO and #ESMOGI with experts in the field!
Please see below the agenda and join us!

Welcome!👋

We are a global, open access, expert-led video journal bringing healthcare professionals trustworthy, cutting-edge news in #Oncology🔦

🏥Disease areas www.vjoncology.com/subjects/#all

🎧VJOncology Podcast www.vjoncology.com/podcasts/

📩VJOncology Newsletter www.vjoncology.com/newsletter/

Glad to chair the @vjoncology.bsky.social webinar on #GI cancer and discuss the most important data presented at #ASCO and #ESMOGI with experts in the field!
Please see below the agenda and join us!

Lorenza Rimassa: New Survival Benchmark for People Living with Advanced Biliary Tract Cancer - OncoDaily Lorenza Rimassa: New Survival Benchmark for People Living with Advanced Biliary Tract Cancer / Aiwu Ruth He, Aleksandra Kuzko, Arndt Vogel, Biliary tract

New Survival Benchmark for People Living with Advanced Biliary Tract Cancer - Lorenza Rimassa
@lorenzarimassa.bsky.social

oncodaily.com/science/lore...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GIOnc #BiliaryTractCancer

Longitudinal study sets new survival benchmark for patients with advanced biliary tract cancer In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the...

Longitudinal study sets new survival benchmark for patients with advanced biliary tract cancer | EurekAlert! www.eurekalert.org/news-release...

25 Posts Not To Miss From ESMO GI 2025 - OncoDaily The ESMO Gastrointestinal Cancers Congress (ESMO GI 2025) took place in Barcelona, Spain, from from July 2 to July 5, uniting global oncology professionals committed to improving outcomes across the s...

25 Posts Not To Miss From ESMO GI 2025
@myesmo.bsky.social
@lorenzarimassa.bsky.social
@arndtvogel.bsky.social
@ermanakkus.bsky.social
@rachnatshroff.bsky.social

oncodaily.com/societies/25...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOGI25 #ESMO #GIOnc

#TeresaMacarulla nicely summarizes new data on #HPB cancers presented at #ESMOGI2025 #HCC #BTC #CCA #PDAC #ESMOAmbassadors @myesmo.bsky.social Post n.2

#TeresaMacarulla nicely summarizes new data on #HPB cancers presented at #ESMOGI2025 #HCC #BTC #CCA #PDAC #ESMOAmbassadors @myesmo.bsky.social

@myesmo.bsky.social updated guidelines and living guidelines on #GI cancers presented by #MichelDucreux at #ESMOGI2025 #ESMOAmbassadors

Patient’s perspective presented by #ZoranaMaravic @digestivecancerseu.bsky.social at #ESMOGI2025 #ESMOAmbassadors @myesmo.bsky.social

Promising results of olaparib as a potential new #PrecisionOncology treatment for patients with biliary tract cancer #BTC #CCA and aberrant #HRR mutations. #ESMOGI25 #ESMOAmbassadors @myesmo.bsky.social

Prof Tabernero lecture on lessons learned from #GI translational research and the path forward at #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors

Preliminary efficacy results of the phase 3b ProvIDHe study of #ivosidenib in patients with #IDH1- mutated cholangiocarcinoma #CCA at #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors

Positive phase 2 data of #olaparib in patients with advanced biliary tract cancer #BTC #CCA with aberrant #HRR mutations presented today at #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors

📢 #HealthierEurope. Better access. ESMO welcomes the @ec.europa.eu ’s Life Sciences Strategy - a bold step to reform #IVDR & support clinical innovation. Let’s ensure Europe leads in life sciences & #PatientsCare.
🔗 buff.ly/34j9638

#BrunoSangro discusses #fibrolamellar HCC at #ESMOGI25. Quoting Prof Sangro “This is a call to action since #FLC is a rare disease but shouldn’t be neglected” and I cannot agree more. Post n.2. @myesmo.bsky.social
#ESMOAmbassadors

#BrunoSangro discusses #fibrolamellar HCC at #ESMOGI25. Quoting Prof Sangro “This is a call to action since #FLC is a rare disease but shouldn’t be neglected” and I cannot agree more. Post n.1. @myesmo.bsky.social
#ESMOAmbassadors

I had the honor to discuss the TALENTACE phase 3 trial of on-demand TACE+atezo-bev in patients with intermediate stage #HCC. Positive #PFS, high response rate, OS data non mature. Looking forward to seeing more mature results! #ESMOGI25 #ESMOAmbassadors @myesmo.bsky.social

Novel data in advanced #HCC presented at #ESMOGI25: combination of targeted agents and immunotherapy and of immunotherapy -STRIDE- for patients with poor prognosis. @myesmo.bsky.social #ESMOAmbassadors

#AngelaLamarca discusses new hopes and new combinations for biliary tract cancer #BTC #CCA at #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors

Proffered Paper Session 1 is getting started at #ESMOGI25. Brand new data in GI cancers! @myesmo.bsky.social #ESMOAmbassadors